All In Biotech

Drug Trial Radar · NCT05162768

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower

Last checked: Nov 20, 2026Latest source record: Oct 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

102

Actual

Start

Apr 29, 2022

Primary completion

Sep 30, 2024

Study completion Dec 4, 2024

Sponsor

Lead sponsor
Stealth BioTherapeutics Inc.Industry
Sponsor type
Industry
First posted
Dec 17, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).

Conditions

  • Mitochondrial Myopathies
  • Mitochondrial Pathology
  • Mitochondrial DNA Mutation
  • Mitochondrial Diseases
  • Mitochondrial DNA Deletion
  • Mitochondrial DNA Depletion
  • Mitochondrial Metabolism Defect
  • Mitochondrial Complex I Deficiency

Interventions

  • ElamipretideDrug

    60 mg of elamipretide administered as once daily 0.75 mL subcutaneous injections for 48 weeks

  • PlaceboDrug

    Placebo administered as once daily 0.75 mL subcutaneous injections for 48 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Six-minute walk test (6MWT)Time frame: Baseline, Weeks 12, 24, 36, 48, 52 (End of Trial Visit)

Locations

32 sites in 10 countries. Site status is shown where the registry gives one.

  • University of California, San Diego

    San Diego, California

  • Rare Disease Research, LLC

    Atlanta, Georgia

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center College of Physician and Surgeon

    New York, New York

  • Akron Children's Hospital

    Akron, Ohio

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • University of Pittsburgh School of Medicine Children's Hospital of Pittsburgh of UPMC Department of Genetics

    Pittsburgh, Pennsylvania

  • UT Health,Center for the Treatment of Pediatric Neurodegenerative Disease

    Houston, Texas

  • Royal North Shore Hospital Neurology

    Sydney, New South Wales, Australia

  • Calvary Health Care Bethlehem

    Parkdale, Victoria, Australia

  • Universitaetsklinikum Carl Gustav Carus Dresden Neurologie

    Dresden, Germany

  • Univ of Tubingen, Hertie Institute for Clinical Brain Research

    Tübingen, Germany

  • Department of Neurology, University Clinics Munich

    Munich, Bavaria, Germany

  • Semmelweis Egyetem Genomikai Medicina es Ritka Betegsegek

    Budapest, Hungary

  • University of Pécs, Department of Neurology Klinikai Kozpont - neurologiai Klinika

    Pécs, Hungary

  • IRCCS Institute of Neorological Sciences of Bologna Bellaria Hospital

    Bologna, Italy

  • Azienda Ospedaliero Universitaria Policlinico G. Martino

    Messina, Italy

  • Istituto Nazionale Neurologico Carlo Besta

    Milan, Italy

  • Azienda Ospedaliero Universitario Pisana, Dipartimento Ambientale di Neuroscienze

    Pisa, Italy

  • University of Brescia, NeMO Clinical Center for Neuromuscular Diseases

    Gussago, Brescia, Italy

  • Istituto di Neurologia, Fondazione Policlinico Universitario A. Gemelli, Università Cattolica del Sacro Cuore

    Rome, Lazio, Italy

  • Radboud University Medical Center

    Nijmegen, Netherlands

  • University of Auckland - Auckland City Hospital, Neurology Department

    Auckland, New Zealand

  • Helse Bergen HF

    Bergen, Norway

  • Hospital de la Sta Creu i Sant Pau

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital la Fe de Valencia

    Valencia, Spain

  • University of Cambridge, Department of Clinical Neurosciences

    Cambridge, United Kingdom

  • Queen Square Centre for Neuromuscular Diseases The National Hospital for Neurology and Neurosurgery

    London, United Kingdom

  • Newcastle upon Tyne Hospitals Freeman Hospital

    Newcastle, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.